# US 2022/0346837 A1 · Non-invasive egg retrieval protocols and methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0346837 A1
- Document ID: US20220346837A1
- Status: Published application
- Kind: A1
- Application number: 17/734,799
- Filed: 2022-05-02
- Published: 2022-11-03
- Earliest claimed: 2021-05-03
- Assignees: Butterfly Biosciences, Inc.
- Applicants: Butterfly Biosciences, Inc.
- Inventors: Sam Najmabadi; Moses Cesario; Alexander Nadal; Steven T. Nakajima; José Luis Rivas; Ricardo Peraza
- Web page: https://patentgrep.com/patent/US20220346837A1

## CPC

- A61B 17/435: for embryo {or ova} transplantation
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0034: {Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants}
- A61K 38/09: Luteinising hormone-releasing hormone [LHRH] {, i.e. Gonadotropin-releasing hormone [GnRH]}; Related peptides
- A61K 38/24: Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
- A61P 15/08: for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- C12N 5/0604: {Whole embryos; Culture medium therefor}
- A61B 2017/4216: {Operations on uterus, e.g. endometrium}
- A61M 2210/145: Embryo, fetus
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}

## Abstract

Methods for non-invasive retrieval of viable (i.e., able to be fertilized) oocytes from the uterus via a combination of unique ovarian stimulation and uterine lavage technology. These methods may eliminate the need for an invasive surgical procedure. Embodiments include the use of a novel hormonal protocol, including the use of injectable gonadotropins, to induce the release of immature oocytes from the ovaries of a patient. The immature oocytes mature as they transit the fallopian tubes such that mature, viable oocytes may be collected from the uterus via a uterine lavage procedure. Further embodiments include the use of a novel hormonal protocol, including the administration of Prostaglandins, Estradiol, and/or Progesterone Blockers, to accelerate transport of oocytes through the fallopian tubes. Further embodiments include kits for uterine lavage, compositions suitable for triggering and inducing superovulation, and compositions suitable for accelerating tubal transport of mature oocytes in a female patient.

## Claims

### Claim 1

A kit for uterine lavage, consisting of: a uterine lavage catheter configured for insertion into a woman's uterus to remove oocytes from the uterus; and one or more first containers with a sufficient dosage amount of an injectable gonadotropin over a period of 3 to 9 days to produce a plurality of mature oocytes in the women's uterus, wherein the kit does not include a GnRH antagonist.

### Claim 2 (depends on 1)

The kit of claim 1, wherein the total dosage amount of the injectable gonadotropin to induce superovulation is between about 37.5 to 300 IU's per day.

### Claim 3 (depends on 1)

The kit of claim 1, further comprising instructions for use for administering the injectable hCG trigger at a dosage of between about 1000 to 10000 IU's when dominant follicle is at or between 8-18 mm.

### Claim 4 (depends on 3)

The kit of claim 3, further comprising instructions for use for administering the injectable gonadotropin at a dosage of about 150 IU's per day over the first three days and a dosage of about 100 IU's per day over the next six days.

### Claim 5 (depends on 1)

The kit of claim 1, further including instructions for use for administering a single or multiple dose of urinary or recombinant hCG nasally, orally, subcutaneously, intramuscularly, transdermally, vaginally, rectally, or buccal route to trigger ovulation.

### Claim 6

A kit for uterine lavage, comprising a uterine lavage catheter configured for insertion into a woman's uterus to remove mature oocytes from the uterus; one or more first containers with a sufficient dosage amount of an injectable gonadotropin to produce a plurality of mature oocyte, one or more second containers comprising a GnRH antagonist to prevent early ovulation, and one or more third containers comprising a progesterone receptor blocker, estradiol, and/or a prostaglandin to accelerate tubal transport of the mature oocytes.

### Claim 7

A composition suitable for triggering and inducing superovulation in a female patient over a period of 3 to 11 days to produce a plurality of mature oocytes in the women's uterus, wherein the composition includes a dosage amount of an injectable gonadotropin of between about 500 to 10000 IU's.

### Claim 8

A composition suitable for accelerating tubal transport of mature oocytes in a female patient over a period of 1 to 6 days, comprising a progesterone receptor blocker at a dosage amount of between 100-2,000 mg, estradiol at a dosage amount of between 2-10 mg/day, and/or a prostaglandin at a dosage amount of between 20-1600 mg.

### Claim 9

A method of inducing superovulation in a female patient to produce a plurality of mature oocytes in the uterus of the patient, the method comprising administering an injectable gonadotropin to produce a plurality of oocytes wherein the gonadotropin is administered daily for up to eleven days or until the dominant follicle is at or between 8-18 mm in diameter as confirmed by ultrasound imaging of the ovaries.

### Claim 10 (depends on 9)

The method of claim 9, including administering the gonadotropin over a period of between three to nine days.

### Claim 11 (depends on 10)

The method of claim 10, including administering the gonadotropin over a period of three to six days.

### Claim 12 (depends on 9)

The method of claim 9, wherein the gonadotropin is administered at a dosage amount of between about 37.5 to 300 IU per day over a period of three to 9 days.

### Claim 13 (depends on 12)

The method of claim 12, wherein the gonadotropin is administered at a dosage amount of about 150 IU per day over the first three days and 100 IU per day over the following six days.

### Claim 14

A method of retrieval of a plurality of mature oocytes from the uterus of a female patient, the method comprising administering an injectable gonadotropin to produce a plurality of oocytes wherein the gonadotropin is administered daily for up to eleven days or until the dominant follicle is at or between 8-18 mm in diameter as confirmed by ultrasound imaging of the ovaries, administering one or more agents to the female patient to accelerate tubal transport of the plurality of oocytes, and performing uterine lavage to remove the plurality of mature oocytes from the uterus of the patient.

### Claim 15 (depends on 14)

The method of claim 14, wherein the one or more agents comprise a progesterone receptor blocker, estradiol, and/or a prostaglandin.

### Claim 16 (depends on 14)

The method of claim 14, uterine lavage is performed approximately 10-108 hours after administering gonadotropin.
